Awareness campaign shows signs of delaying onset of drug-resistant gonorrhea in UK

April 14, 2014

In 2012, there were over 25,000 cases of gonorrhoea in the UK making it the second most common bacterial sexually transmitted infection after chlamydia. Control of gonorrhoea is dependent on successful antibiotic treatment, as the bacterium that causes the infection, Neisseria gonorrhoeae, has become increasingly resistance to every antibiotic used to treat it over the last 60 years. Today, at the Society for General Microbiology's Annual Conference in Liverpool, Professor Cathy Ison explains the challenges facing the treatment of the disease, which threatens to become resistant to all antibiotics.

In 2012, Professor Ison led on the launch of the Health Protection Agency's first Gonorrhoea Resistance Action Plan for England and Wales, as part of the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) that provides on levels of . GRASP, which has provide surveillance data in England and Wales since 2000, has been used to change clinical practice in the UK.

Today, she will show that campaigns in the UK to raise awareness of drug among healthcare professionals, policy-makers and at risk groups have shown some success in delaying the onset of treatment failure to the oral antibiotic cefixime. When evidence of antibiotic-resistance to cefixime was identified it was replaced as treatment of choice by ceftriaxone, an injectable antibiotic of the same class. This was done to prevent the widespread emergence of cefixime-resistance gonorrhoea. Cefixime and ceftriaxone are the last group of antibiotics known to be fully effective against gonorrhoea.

Professor Ison said: "While we have shown that a proactive approach to changing therapy has shown some success, we should remember that this infection has repeatedly become resistant to successive antibiotics over decades, and that it is likely that this is only a temporary reprieve. This will give the internationally community time to investigate new drugs and alternative strategies for treating gonorrhoea and maintain it as a treatable infection."

However, Professor Ison stresses that we should remain vigilant: "We can already see in data from England and Wales, as well as other some countries, that there is the beginning of drifts towards resistance to the injectable drug, ceftriaxone, which is currently used as the drug of choice for gonorrhoea. Public health control of gonorrhoea must include prompt diagnosis, delivery of effective treatment and detection of treatment failures, combined with strong prevention messages."

To combat the continuing high rates of STI transmission in England, and the growing risk of treatment failure it is essential that individuals:

  • Always use a condom when having sex with new and casual partners
  • Reduce the number of sexual partners and avoid overlapping sexual relationships
  • Get a regular STI check-up if having unprotected sex with new or casual partners.

Explore further: Last-line antibiotics increasingly ineffective against gonorrhea

More information: The Society for General Microbiology's Annual Conference 2014 takes place 14-17 April Arena and Convention Centre, Liverpool, UK.

Related Stories

STIs and risky sex still an issue

November 26, 2013

New results from the third National Survey of Sexual Attitudes and Lifestyles (Natsal), published in The Lancet, provide a picture of sexually transmitted infection (STI) prevalence and testing, uptake of sexual health interventions ...

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.